Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May 16;15(5):8753-72.
doi: 10.3390/ijms15058753.

Colonization and infection of the skin by S. aureus: immune system evasion and the response to cationic antimicrobial peptides

Affiliations
Review

Colonization and infection of the skin by S. aureus: immune system evasion and the response to cationic antimicrobial peptides

Sunhyo Ryu et al. Int J Mol Sci. .

Abstract

Staphylococcus aureus (S. aureus) is a widespread cutaneous pathogen responsible for the great majority of bacterial skin infections in humans. The incidence of skin infections by S. aureus reflects in part the competition between host cutaneous immune defenses and S. aureus virulence factors. As part of the innate immune system in the skin, cationic antimicrobial peptides (CAMPs) such as the β-defensins and cathelicidin contribute to host cutaneous defense, which prevents harmful microorganisms, like S. aureus, from crossing epithelial barriers. Conversely, S. aureus utilizes evasive mechanisms against host defenses to promote its colonization and infection of the skin. In this review, we focus on host-pathogen interactions during colonization and infection of the skin by S. aureus and methicillin-resistant Staphylococcus aureus (MRSA). We will discuss the peptides (defensins, cathelicidins, RNase7, dermcidin) and other mediators (toll-like receptor, IL-1 and IL-17) that comprise the host defense against S. aureus skin infection, as well as the various mechanisms by which S. aureus evades host defenses. It is anticipated that greater understanding of these mechanisms will enable development of more sustainable antimicrobial compounds and new therapeutic approaches to the treatment of S. aureus skin infection and colonization.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Toll-like receptor-mediated cutaneous immune response against S. aureus. Toll-like receptor 2 (TLR2) and nucleotide-binding oligomerization domain containing 2 (NOD2), which are expressed by keratinocytes, respectively recognize S. aureus lipopeptides/lipoteichoic acid and muramyl dipeptide. Both TLR2 and NOD2 signaling triggers the activation of nuclear factor-κB (NF-κB), which leads to the production of AMPs, cytokines, chemokines, adhesion molecules and granulopoesis factors, all of which contribute to the cutaneous host defense against S. aureus.
Figure 2.
Figure 2.
IL-1- and IL-17-mediated cutaneous immune response against S. aureus. Infection of the skin by S. aureus leads to the production of IL-1α, IL-1β and IL-17, which in turn triggers activation of nuclear factor-κB (NF-κB). These signaling pathways lead to the production of AMPs, cytokines, chemokines, adhesion molecules and granulopoesis factors, which recruit neutrophils from the circulation to the site of S. aureus infection in the skin. The recruited neutrophils form an abscess that helps control and limit the spread of the infection, and is ultimately required for bacterial clearance. IL-1R1, interleukin-1 receptor 1; IL-17R, interleukin-17 receptor.
Figure 3.
Figure 3.
Strategies by which S. aureus evades CAMPs. S. aureus counteracts CAMPs by secreting trapping molecules and proteases that inactivate CAMPs and by modifying the cell membrane hydrophobicity or net charge [108].

Similar articles

Cited by

References

    1. Chambers H.F. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 2001;7:178–182. - PMC - PubMed
    1. Lowy F.D. Staphylococcus aureus infections. N. Engl. J. Med. 1998;339:520–532. - PubMed
    1. Graham P.L., 3rd, Lin S. X., Larson E.L. A U.S. population-based survey of Staphylococcus aureus colonization. Ann. Intern. Med. 2006;144:318–325. - PubMed
    1. Kuehnert M.J., Kruszon-Moran D., Hill H.A., McQuillan G., McAllister S.K., Fosheim G., McDougal L.K., Chaitram J., Jensen B., Fridkin S.K., et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001–2002. J. Infect. Dis. 2006;193:172–179. - PubMed
    1. Perl T.M., Cullen J.J., Wenzel R.P., Zimmerman M.B., Pfaller M.A., Sheppard D., Twombley J., French P.P., Herwaldt L.A., et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N. Engl. J. Med. 2002;346:1871–1877. - PubMed

Publication types

MeSH terms